Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced that the first participant has been dosed in the phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients. As per the terms of the collaboration deal, Sangamo has now earned a $30 million milestone payment.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced that the first participant has been dosed in the phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients. As per the terms of the collaboration deal, Sangamo has now earned a $30 million milestone payment.

RTTNews | Oct 7, 2020 06:58AM EDT

06:57 Wednesday, October 7, 2020 (RTTNews.com) - Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced that the first participant has been dosed in the phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients. As per the terms of the collaboration deal, Sangamo has now earned a $30 million milestone payment.

Pfizer is now operationally and financially responsible for research, development, manufacturing and commercialization activities for giroctocogene fitelparvovec following the transfer of the Investigational New Drug from Sangamo to Pfizer in December 2019.

Read the original article on RTTNews ( https://www.rttnews.com/3134417/pfizer-sangamo-begin-phase-3-dosing-study-of-giroctocogene-fitelparvovec.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved